Suvorexant shows promise for menopause-related insomnia: study

Clinicians say the orexin receptor antagonist is both well-tolerated and efficacious

Postmenopausal women who experience chronic insomnia may benefit from the dual orexin receptor antagonist suvorexant, a small US study suggests.

Researchers say the drug, which was well-tolerated among participants, could provide a novel therapeutic option for those with vasomotor symptom-associated insomnia.

In the randomised controlled trial, 56 middle-aged women with chronic insomnia associated with night-time vasomotor symptoms (VMS) were assigned to receive either 10-20mg oral suvorexant or placebo